Raloxifene is a selective estrogen-receptor ... There is still much to be learned about SERMs and their mechanism of action. This article reviews what is currently known about the pharmacology ...

Conversely, raloxifene, an FDA-approved second-generation ... Second, how can the opposing effects of SERMs in different tissues in the body be reconciled, and how can these characteristics ...

Although chronic kidney disease (CKD) is associated with an increased likelihood of osteoporosis, the efficacy and safety of therapies for osteoporosis in women with CKD remain unclear. Ishani et al.